Journal of Public Health · 2023 · 18 citations · 26 references
PharmacyOncologyPharmacoeconomicsCancer ControlCost-effectiveness AnalysisPharmacoeconomic ModelingCancer StagingCost-effectiveness ModelingHealthcare Cost AnalysisModel-based Economic EvaluationPharmacoeconomic EvaluationTreatment Pathway ModelingCancer Cost BurdenCancer Registry EvaluationCost-effectiveness Of Cancer ControlDisease Stage AssessmentEconomic Burden Of CancerProbabilistic AnalysisProbabilistic Sensitivity AnalysisTreatment Cost Analysis
BACKGROUND: Management options for the treatment of melanoma have expanded in recent years. In an era of promising, but expensive novel pharmacological treatments, robust stage-specific melanoma-related cost estimates are necessary to support budgetary planning, evaluation of cost-effectiveness and to contribute to the investment case for prevention. METHODS: A detailed decision model, describing the melanoma care pathway (by disease stage) from diagnosis, through treatment and follow-up was developed over a 5-year time frame from the perspective of the Irish healthcare system. The model was populated with real-world data from the National Cancer Registry Ireland. Uncertainty was explored using one-way and probabilistic sensitivity analysis. RESULTS: The cost of managing a case of melanoma diagnosed at Stage IV (€122 985) was more than 25 times more expensive than managing a case diagnosed at Stage IA (€4269). Total costs were sensitive to the choice of immunotherapeutic and targeted drug, duration of treatment and proportion of patients receiving immunotherapy agents. CONCLUSIONS: The rising incidence of melanoma and high cost of new novel therapies presents an immediate challenge to cancer control and public health globally. This study highlights the cost differential between early and late detection and the potential return on investment for prevention versus high-cost treatment.
26
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
Melina Arnold, Deependra Singh, Mathieu Laversanne et al. · JAMA Dermatology · 2022 · 1.4K citations · Full text
Medicine, Dermatology, Oncology +16
Economic Burden of Melanoma in the Elderly Population
Anne M. Seidler, Michelle L. Pennie, Emir Veledar et al. · Archives of Dermatology · 2010 · 103 citations
Measuring current and future cost of skin cancer in England
Laura Vallejo‐Torres, Stephen Morris, Jonas Minet Kinge et al. · Journal of Public Health · 2013 · 103 citations
Medicine, Health Policy, Oncology +17
Ulrike Leiter, Petra Buettner, Thomas Eigentler et al. · Journal of the American Academy of Dermatology · 2011 · 99 citations · Full text
Medicine, Dermatology, Oncology +12